SNTI Key Statistics, Chart & Performance
The current stock price of SNTI is 1.13 USD. In the past month the price decreased by -49.1%. In the past year, price decreased by -71.25%.
SNTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.3 | 389.14B | ||
| AMGN | AMGEN INC | 14.66 | 172.70B | ||
| GILD | GILEAD SCIENCES INC | 14.44 | 146.77B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.85 | 113.87B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.96 | 80.22B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.06 | 52.56B | ||
| INSM | INSMED INC | N/A | 37.36B | ||
| NTRA | NATERA INC | N/A | 32.77B | ||
| BIIB | BIOGEN INC | 10.43 | 25.62B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.56 | 21.09B | ||
| INCY | INCYTE CORP | 15.86 | 19.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B |
Related stock screener links
About SNTI
Company Profile
Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2021-05-26. The firm is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
Company Info
SENTI BIOSCIENCES INC
2 Corporate Drive, First Floor
South San Francisco CALIFORNIA US
Employees: 34
Phone: 16502392030
SENTI BIOSCIENCES INC / SNTI FAQ
What does SENTI BIOSCIENCES INC do?
Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2021-05-26. The firm is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
What is the current price of SNTI stock?
The current stock price of SNTI is 1.13 USD. The price increased by 2.73% in the last trading session.
What is the dividend status of SENTI BIOSCIENCES INC?
SNTI does not pay a dividend.
What is the ChartMill rating of SENTI BIOSCIENCES INC stock?
SNTI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is SENTI BIOSCIENCES INC (SNTI) stock traded?
SNTI stock is listed on the Nasdaq exchange.
How many employees does SENTI BIOSCIENCES INC have?
SENTI BIOSCIENCES INC (SNTI) currently has 34 employees.
Can you provide the short interest for SNTI stock?
The outstanding short interest for SENTI BIOSCIENCES INC (SNTI) is 14.63% of its float.
SNTI Technical Analysis
SNTI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNTI. The financial health of SNTI is average, but there are quite some concerns on its profitability.
SNTI Financial Highlights
Over the last trailing twelve months SNTI reported a non-GAAP Earnings per Share(EPS) of -2.79. The EPS increased by 82.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -90.31% | ||
| ROE | -585.9% | ||
| Debt/Equity | 0 |
SNTI Forecast & Estimates
10 analysts have analysed SNTI and the average price target is 11.73 USD. This implies a price increase of 938.05% is expected in the next year compared to the current price of 1.13.
For the next year, analysts expect an EPS growth of 81.81% and a revenue growth -76.19% for SNTI